top of page

Investors

Rectangle 176.png

>€10B

Total adressable market

China

>€3B

23%

Up affected population​

China

16%

Join the forefront of phlebology treatments!

Promising market prospects

  • A huge potential market in Europe : 235m patients

  • Potential for future value creation (~80M€+ projected revenue in 2030)

An exclusive worldwide licence with Inserm

  • Committed founders and a highly qualified and experienced team

  • Six years of research and development in ultrasound technology

An unmet clinical need for a safe, rapid and painless therapy

  • A non-invasive, comfortable approach to meet the needs of patients and doctors

  • A differentiated and validated non-thermal HIFU technology

    • A non-invasive, comfortable approach to meet the needs of patients and doctors

    • A differentiated and validated non-thermal HIFU technology

    • Committed founders and a highly qualified and experienced team

    • Six years of research and development in ultrasound technology​

    • A huge potential market in Europe : 235m patients

    • Potential for future value creation (~80M€+ projected revenue in 2030)

Why invest ?

Outstanding Exits

A dynamic and active acquisition market in the last decade

2009

$440m

Covidien acquired VNUS inc.

2014

$220m

Covidien acquired Sapheon

$660

Merz acquired Ulthera inc.

2021

+$500m

BD acquired Venclose

2009

2014

2021

+$500m

BD acquired Venclose

$660m

Merz acquired Ulthera inc.

$220m

Covidien acquired Sapheon

$440m

Covidien acquired VNUS inc.

Outstanding Exits

A dynamic and active acquisition market in the last decade

A breakthrough technology

COMPANIES

NON-INVASIVE

PAINLESS

FAST

OFFICE-BASED

NON-THERMAL

ULTRASOUND

FOAM

GLUE

Untitled.png

Concurent

Concurent

ULTRASOUND

FOAM

GLUE

THERMAL

THERMAL ABLATION

ULTRASOUND

Concurent

Concurent

News & Press releases

July 00th 2024

Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus.

Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus. Interdum tristique cursus scelerisque donec mi nunc quis.

July 00th 2024

Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus.

Lorem ipsum dolor sit amet consectetur. Massa enim viverra viverra sodales lacus. Interdum tristique cursus scelerisque donec mi nunc quis.

picture-article-veinsound-non-invasive-treatment-of-varicose-veins.png

July 7, 2025

Vascular physicians try the Veinsound probe at the SFMV congress in Reims

Two minutes at the SFMV congress in Reims: vascular physicians took the probe in hand on our booth and told us what they expect from it.

Medinov.jpg

October 8, 2026

Vascular physicians try the Veinsound probe at the SFMV congress in Reims

Two minutes at the SFMV congress in Reims: vascular physicians took the probe in hand on our booth and told us what they expect from it.

Medinov.jpg

September 16, 2026

Veinsound announces the successful launch of EASY-VEIN NT, a first-in-human study

Study authorized under the EU Medical Device Regulation (EU) 2017/745. First procedures completed as planned, in an office setting and without anesthesia. Study completion is expected in Q1 2027.

Medinov.jpg

January 28, 2026

Advancing the treatment of varicose veins: Veinsound at the 83rd SFP Congress

Discover Veinsound’s non-invasive focused ultrasound technology for the treatment of varicose veins, presented at the 83rd SFP Congress and praised by phlebologists.

July 00th 2024

Lorem ipsum dolor sit amet consectetur massa enim.

June 00th 2024

Lorem ipsum dolor sit amet consectetur massa enim.

Want to know more about our product ?

Learn more

Contact us to know more about Veinsound

We will answer you as soon as possible

Contact us to know more about Veinsound

We will answer you as soon as possible

bottom of page